Intervention not reported
Viral clearance at 14 days · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality at day 28 · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life up to 28 days and longest · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Viral clearance at 7 days · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
It is very uncertain whether the intervention changes viral clearance at 7 days (very low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at 14 days · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
It is very uncertain whether the intervention changes viral clearance at 14 days (very low certainty).
1 finding from 1 review
Intervention not reported
All initial symptoms resolved at 28 days, and up to the longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life up to 28 days and longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
Caffeine showed no clear difference in bronchopulmonary dysplasia/chronic lung disease: defined as 28 days… compared with other methylxanthines (low certainty).
1 finding from 1 review
RR 1.4 [0.92, 2.11]
Studies not reported
Low
Length of hospital stay · preterm infants
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Rate of orthodontic tooth movement during space closure stage (maxillary canine distalisation), mm/day · Adolescents and adults with malocclusion undergoing fixed orthodontic appliance treatment
It is very uncertain whether light-emitting diode (LED) photobiomodulation changes rate of orthodontic tooth movement during space closure stage… compared with conventional orthodontic appliance treatment (very low certainty).
1 finding from 1 review
Mean time to resolution of pain · Adults (>18 years) with established dry socket following permanent tooth extraction
Neocone led to lower time to complete resolution of pain (days) compared with alvogyl; GRADE not reported.
1 finding from 1 review
Mean time to resolution of pain · Adults (>18 years) with established dry socket following permanent tooth extraction
Alvogyl led to lower time to complete resolution of pain (days) compared with zinc oxide eugenol; GRADE not reported.
1 finding from 1 review
Duration of treatment (days) · Adults (>18 years) with established dry socket following permanent tooth extraction
Metronidazole (intrasocket) led to lower duration of treatment (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Mean time to resolution of pain · Adults (>18 years) with established dry socket following permanent tooth extraction
Neocone led to lower time to complete resolution of pain (days) compared with zinc oxide eugenol; GRADE not reported.
1 finding from 1 review
Stroke · patients undergoing carotid endarterectomy, whether the initial indication for endarterectomy was symptomatic or asymptomatic carotid…
It is very uncertain whether main comparison of patch angioplasty changes any stroke (fatal or non‐fatal; contralateral, ipsilateral or… compared with primary closure (very low certainty).
1 finding from 1 review
Perioperative ipsilateral stroke (< 30 days) · patients undergoing carotid endarterectomy, whether the initial indication for endarterectomy was symptomatic or asymptomatic carotid…
It is very uncertain whether main comparison of patch angioplasty changes ipsilateral stroke (fatal or non‐fatal; haemorrhage or infarct)… compared with primary closure (very low certainty).
1 finding from 1 review
Occlusion of the operated artery within 30 days of operation · patients undergoing carotid endarterectomy, whether the initial indication for endarterectomy was symptomatic or asymptomatic carotid…
Main comparison of patch angioplasty may leads to lower occlusion of the operated artery within 30 days of operation compared with primary closure (low certainty).
1 finding from 1 review
Death from all causes within 30 days of surgery · patients with symptomatic or asymptomatic carotid disease
Shunting showed no clear difference in death from all causes within 30 days of surgery compared with no shunting (low certainty).
1 finding from 1 review
Stroke‐related death within 30 days of surgery (best‐case) · patients with symptomatic or asymptomatic carotid disease
Shunting may leads to lower stroke‐related death within 30 days of surgery (best‐case) compared with no shunting (low certainty).
1 finding from 1 review
Stroke‐related death within 30 days of surgery (worst‐case) · patients with symptomatic or asymptomatic carotid disease
Shunting showed no clear difference in stroke‐related death within 30 days of surgery (worst‐case) compared with no shunting (low certainty).
1 finding from 1 review